Polypid Stock In The News

PYPD Stock  USD 2.98  0.04  1.36%   
Our overall analysis of PolyPid's news coverage and content from conventional and social sources shows investors' bearish mood towards PolyPid. The specific impact of PolyPid news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of PolyPid's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using PolyPid headlines in addition to utilizing other, more conventional financial analysis modules. Check out PolyPid Backtesting and PolyPid Hype Analysis.
For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.

PolyPid Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
https://www.globenewswire.com/news-release/2025/01/30/3017860/0/en/PolyPid-to-Participate-in-the-Oppenheimer-35th-Annual-Healthcare-Life-Sciences-Conference.html
 Bullish
Macroaxis News: globenewswire.com
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
https://www.globenewswire.com/news-release/2025/01/29/3017023/0/en/PolyPid-to-Report-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Operational-Highlights-on-February-12-2025.html
 Bullish
Macroaxis News: globenewswire.com
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/08/2776036/0/en/PolyPid-Provides-Corporate-Update-and-Reports-Third-Quarter-2023-Financial-Results.html
 Neutral
Macroaxis News: globenewswire.com
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
https://www.globenewswire.com/news-release/2023/11/07/2774914/0/en/PolyPid-Announces-the-Addition-of-Dr-Nurit-Tweezer-Zaks-to-its-Board-of-Directors.html
 Neutral
Macroaxis News: globenewswire.com
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023
https://www.globenewswire.com/news-release/2023/11/01/2770972/0/en/PolyPid-to-Report-Third-Quarter-2023-Financial-Results-and-Operational-Highlights-on-November-8-2023.html
 Bullish
Macroaxis News: globenewswire.com
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
https://www.globenewswire.com/news-release/2023/10/11/2758188/0/en/PolyPid-Regains-Compliance-with-Nasdaq-Minimum-Closing-Bid-Price-Rule.html
 Neutral
Macroaxis News: globenewswire.com
PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
https://www.globenewswire.com/news-release/2023/10/09/2756567/0/en/PolyPid-Announces-Presentation-at-the-American-College-of-Surgeons-Clinical-Congress-2023.html
 Bullish
Macroaxis News: globenewswire.com
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform
https://www.globenewswire.com/news-release/2023/10/04/2754436/0/en/PolyPid-Announces-Publication-of-Preclinical-Data-Further-Supporting-the-Good-Safety-Profile-of-D-PLEX-and-PLEX-Technology-Platform.html
 Neutral
Macroaxis News: globenewswire.com
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
https://www.globenewswire.com/news-release/2023/09/22/2747883/0/en/PolyPid-to-Present-at-the-2023-Cantor-Fitzgerald-Global-Healthcare-Conference.html
 Bullish
Macroaxis News: globenewswire.com
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
https://www.globenewswire.com/news-release/2023/09/21/2747174/0/en/PolyPid-Announces-Successful-Commercial-Good-Manufacturing-Practice-GMP-Audit-by-Israeli-Ministry-of-Health.html
 Neutral

PolyPid Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide PolyPid and other traded companies coverage with news coverage. We help investors stay connected with PolyPid headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on PolyPid Stock performance. Please note that trading solely based on the PolyPid hype is not for everyone as timely availability and quick action are needed to avoid losses.
PolyPid's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help PolyPid investors visualize upcoming and past events in order to time the market based on PolyPid noise-free hype analysis.
PolyPid stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the PolyPid earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about PolyPid that are available to investors today. That information is available publicly through PolyPid media outlets and privately through word of mouth or via PolyPid internal channels. However, regardless of the origin, that massive amount of PolyPid data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of PolyPid news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of PolyPid relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to PolyPid's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive PolyPid alpha.

PolyPid Largest EPS Surprises

Earnings surprises can significantly impact PolyPid's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-11-11
2020-09-30-0.39-0.350.0410 
2022-11-09
2022-09-30-0.54-0.480.0611 
2023-02-08
2022-12-31-0.41-0.320.0921 
2021-11-10
2021-09-30-0.62-0.530.0914 
2021-02-10
2020-12-31-0.51-0.410.119 
2022-02-09
2021-12-31-0.56-0.71-0.1526 
View All Earnings Estimates

PolyPid Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to PolyPid Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
11th of March 2025
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX...
at gurufocus.com 
Gurufocus Stories at Macroaxis
13th of February 2025
PolyPid Ltd Q4 2024 Earnings Call Highlights Strategic Advances Amid Rising RD Costs
at gurufocus.com 
seekingalpha News
12th of February 2025
PolyPid targets SHIELD II trial completion with top-line results in Q2 2025
at seekingalpha.com 
Gurufocus Stories at Macroaxis
30th of January 2025
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
at gurufocus.com 
Macroaxis News: globenewswire.com
29th of January 2025
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational High...
at globenewswire.com 
seekingalpha News
21st of January 2025
PolyPid files for secondary offering
at seekingalpha.com 
Google News at Macroaxis
26th of December 2024
PolyPid stock poised for 2026 launch despite adjusted target from H.C. Wainwright By Inves...
at news.google.com 
Yahoo News
24th of December 2024
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD...
at finance.yahoo.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PolyPid in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PolyPid's short interest history, or implied volatility extrapolated from PolyPid options trading.
When determining whether PolyPid is a strong investment it is important to analyze PolyPid's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact PolyPid's future performance. For an informed investment choice regarding PolyPid Stock, refer to the following important reports:
Check out PolyPid Backtesting and PolyPid Hype Analysis.
For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PolyPid. If investors know PolyPid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PolyPid listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.91)
Return On Assets
(0.86)
Return On Equity
(10.39)
The market value of PolyPid is measured differently than its book value, which is the value of PolyPid that is recorded on the company's balance sheet. Investors also form their own opinion of PolyPid's value that differs from its market value or its book value, called intrinsic value, which is PolyPid's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PolyPid's market value can be influenced by many factors that don't directly affect PolyPid's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PolyPid's value and its price as these two are different measures arrived at by different means. Investors typically determine if PolyPid is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PolyPid's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.